Pfizer, Astellas end Caduet agreement in Japan; Novartis' Ultibro tops Advair in COPD study;

> Pfizer Japan and Astellas Pharma have agreed to terminate the Japanese distribution and copromotion agreement for Caduet combo tablets at the end of next March. Report

> New data shows that Novartis' ($NVS) once-daily Ultibro Breezhaler was superior in reducing COPD flare-ups compared with GlaxoSmithKline's ($GSK) Seretide, known as Advair in the U.S. Release

> ThromboGenics' Jetrea has won approval in South Korea. Release

> Mylan ($MYL) will acquire the U.S. rights to DVT drug Arixtra from Aspen. Release

> An FDA advisory committee has recommended against approval of Actavis' ($ACT) Nebivolol/Valsartan fixed-dose combination NDA for the treatment of hypertension. Release

> Omnicom's Adelphi Worldwide has purchased healthcare brand and research agency The Planning Shop international. Story

> Johnson & Johnson ($JNJ) Vision Care is offering a new range of promotional materials designed to help opticians attract, convert and retain contact lens patients. More

And Finally... AmerisourceBergen's ($ABC) new ad campaign uses a mirror concept to illustrate how the company creates a unified brand. More

Suggested Articles

Forget the charts and graphs, sales reps. Lead with your heart instead. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded…

GW Pharma created a virtual reality voyage to allow doctors to see for themselves its pharma-quality growing operations and process.

Sanofi turned to a mobile, augmented reality approach to promote its allergy drug Allegra in Brazil.